Palatin's stock rockets after FDA OK to market sexual desire disorder treatment MarketWatchFDA erred on women's libido drug; don't reward Palatin Technologies STATRegulators approve shot to boost women's sex drive New York Post Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women TheStreet.comWhy This New FDA-approved Drug Vyleesi Is Not 'Female Viagra' ForbesView full coverage on Google News